INTRODUCTION
The source of hematopoietic stem cells (HSCs) for allogeneic transplantation has been evolving over the last decades, from the use of unstimulated bone marrow (BM) to G-CSF-mobilized peripheral blood (PB), G-CSF-primed BM (G-BM) and cord blood.
1 G-CSF-mobilized PBSC has replaced BM as the most commonly used source of allogeneic stem cells. Data from the Center for International Blood and Marrow Transplant Research indicate that in adults 420 years of age, from 2007-2011, PB collections accounted for 80% and BM accounted for 15% of the source of stem cells worldwide. 2 Allogeneic HSC transplantation is an established treatment option for many malignant and nonmalignant disorders. In the past two decades, PBSCs replaced BM as the stem cell source due to faster engraftment and practicability. 3 As transplant indications and conditioning regimens continue to change, whether the choice of the stem cell source has an impact on transplant outcomes remains to be determined.
Each source of HSC has a unique number and content of CD34+ cells, different natural killer and T-cell subtypes, and possibly other cellular components, which affect the time frame of hematopoietic recovery, incidence of acute and chronic GvHD and relapse rate, and thus may dictate the choice for grafting under different situations. G-BM or filgrastim-primed BM is one of the sources of HSC, with several studies demonstrating the safety and feasibility of this approach with the potential for reducing some allograft-related problems such as acute and chronic GvHD, and accelerating engraftment.
In this study, we will review the evidence supporting this approach by examining the hematopoietic characteristics of such a graft, the incidence of GvHD and relapse, and the risk that using such an approach has for the donors.
G-BM HEMATOPOIETIC STEM CELLS: ORIGIN OF THE CONCEPT
Blood progenitor cell mobilization in humans was initially noted during recovery after myelosuppressive chemotherapy. Subsequent studies [4] [5] [6] [7] [8] [9] [10] suggested that G-CSF administration might also increase the content of progenitor cells in the BM and change their biological characteristics as well, making them similar to PBSC. [10] [11] [12] [13] This became the background of clinical trials that confirmed that the kinetics of engraftment with G-BM was as rapid as engraftment with G-CSF-mobilized PBSC, initially in autografts [14] [15] [16] [17] [18] and then in related donor allografts, the subject of this review.
The use of HSC collected from PB also leads to collection of 10-fold more T lymphocytes, which accounts for the higher incidence of GvHD after PBSC allografting. It has now been demonstrated that the administration of G-CSF to a donor before marrow collection allows for the collection of more CD34+ progenitor cells as compared with unstimulated marrow, but without the large number of T lymphocytes present in unmanipulated PBSC. [19] [20] [21] [22] The relative risk (RR) of developing clinical chronic extensive GvHD by 2 years among patients who had received PBSC grafts as compared with BM grafts in related donors 23 was 2.37 (95% confidence interval: 1.07-5.29, P = 0.035). This was also shown in unrelated donors 24 where extensive chronic GvHD was significantly more common in the PBSC group compared with the BM group (39% vs 24%, P = 0.03).
EFFECT OF PRE-COLLECTION OF G-CSF ADMINISTRATION ON THE PROGENITOR CONTENT OF BM
The effect of G-CSF on the hematopoietic progenitor cell content in normal individuals has been studied over the last decade. Two studies have looked at the short-term effect of G-CSF administration in almost similar doses of 5-10 μg/kg/day for 4-5 days on BM progenitor cells collected from normal BM donors. Those studies showed that the total nucleated cells and absolute numbers of CD34+ cells per milliliter showed similar response kinetics in both BM and PB, with peaks at days 5 and 6, respectively, followed by a return to baseline after 1-2 weeks. There were reciprocal changes in the percentage of CD34+ cells in the BM and PB compartments, confirming the concept of mobilization. As the administration of G-CSF for 5 days will reduce the number of progenitor cells in the BM, as they are mobilized into the PB, a briefer course of G-CSF was deemed to be enough to improve the myeloid-engrafting capacity of the BM. [11] [12] Five days of G-CSF administration resulted in a higher number of BM colony-forming unit-granulocyte-monocyte and burst-forming unit-erythrocyte, as compared with untreated historical controls. 15, 25, 26 In addition, immunological properties of grafts from PB and BM have been examined. The absolute numbers of lymphocytes, monocytes, CD4 (+), CD3 (+) and CD8 (+) T cells, and dendritic cells (DC1 and DC2) were higher in mobilized blood than in mobilized marrow. The ratio of CD4/CD8 in G-CSF-PB was also significantly higher than that in G-BM (P o0.001). The quantities of interferon-γ (IFN-γ) and interleukin-4 (IL-4) secreted by T cells per microliter of G-CSF-PB was significantly higher than those of G-CSF-BM and the ratio of IL-4/IFN-γ was significantly lower in G-CSF-PB than that in G-CSF-BM (P o0.001). This difference in immunologically active cells and modifying cytokines between the two graft sources may explain the lower incidence of GvHD and lower relapse rate after G-CSF-BM and G-CSF-PB transplantation, respectively. [27] [28] [29] [30] In humans, the magnitude of G-CSF-stimulated increases in CD34+ cell numbers in PB and BM samples was quite different, with maximum increases of 26-fold and 1.5-to 1.7-fold, respectively. 31 There was an~50-fold increase in long-term culture-initiating cell activity and an~90-fold increase in shortterm repopulating cell activity in G-BM, although colony-forming cell numbers showed very little change. Treating healthy donor with G-CSF significantly increased the percentages of IL-4-positive cells in BM-naive CD4+ and CD8+ T-cell subsets. 32 G-CSF can induce BM T-cell hyporesponsiveness and polarize T cells from Th1 to Th2 phenotype. 32 All lymphocyte subsets exhibited 26-to 46-fold higher cell counts and the CD4/CD8 ratio was also significantly higher in G-PB than in G-BM. 33 G-CSF treatment on BMs decreased the quantities of IFN-γ secretion dramatically (P = 0.007) and IL-4 moderately (P = 0.027), leading to higher ratios of IL-4/IFN-γ (P = 0.004). T-cell hyporesponsiveness and lower expression of CD28/CD80/CD86 on monocytes, B and T cells was also confirmed. The number of monocytes per microliter was increased 2.13-fold, while the DC2 were preferentially increased 34 ( Table 1) .
Thus, the use of G-CSF in HSC mobilization from the BM or PB has a tremendous impact on the hematopoietic content of the graft that may have significant implications for the functioning of the transplanted product.
G-BM IN RELATED-DONOR ALLOGENEIC HSC TRANSPLANTATION
Several groups have examined the use of G-BM in the setting of allogeneic BM transplantation from related donors. There are at least six retrospective studies that compare G-BM with steadystate BM in related donor allografts (Table 2) .
Isola et al. 35 reported a pilot study of 10 patients transplanted for various benign and malignant hematological conditions, who received an HLA-identical related-donor BM primed with a G-CSF dose of 10 μg/kg/day for 2 days before the collection. Five out of 20 Couban et al. 19 Ji et al. Abbreviations: BM = bone marrow; CI = confidence interval; G-BM = G-CSF-primed BM; LFS = leukemia-free survival; NA = not applicable; OS = overall survival; Plt = platelet; TNC = total nucleated count; TRM = transplantation-related mortality. a Significant values.
G-BM as source of stem cells U Deotare et al 10 patients received either G-CSF or G/M-CSF from day 0 till engraftment. Compared with untreated historical control BM, stimulated infusions contained similar numbers of CD34+ cells but higher numbers of granulocyte-macrophage colony-forming units. None of the patients had severe chronic GvHD, although the duration of follow-up was short. Isola et al. 20 also reported the outcome (median follow-up, 24 months) of 17 patients who received primed BM (G-CSF dose of 10 μg/day for 2 days before BM collection) from matched sibling donors. Eight out of 17 patients received either G-CSF or G/M-CSF from day 0 until engraftment. The control group consisted of 112 historical patients who had received steady-state BM. Neutrophil engraftment occurred more rapidly in patients receiving primed BM than in those receiving steady-state BM, resulting in shortened median hospitalization. The rate of GvHD of grade 4ІІ and the rate of relapse were identical in primed BM transplant and BM transplant patients (GvHD 18% and 19%, respectively).
Ji et al. 36 reported the effect of G-CSF-stimulated BM on engraftment and incidence of GvHD in allogeneic BM transplantation in 30 patients with leukemia, whose donors were given G-CSF 3-4 μg/kg/day for 7 days before marrow collection. Both groups received G-CSF 3-4 μg/kg/day from day 2 until engraftment. The results were compared with those of 18 historical marrow graft (without G-CSF) recipients. The incidence of grade Ι-ΙΙ acute GvHD was very low (3.3%) with 5/18 patients in the control group manifested with grade ΙΙ acute GvHD (27.8%, P = 0.02). The results of this study suggested that G-CSF-primed graft can accelerate engraftment and minimize the incidence of acute GvHD.
Couban et al. 19 reported a single-arm study of 29 patients who received G-BM. The donor received four consecutive daily injections of G-CSF (median dose 12 μg/kg/day) before BM collection. The BM collection contained a median of 2.5 × 10 6 CD34 cells per kg recipient weight. Median time to neutrophil and platelet engraftment was shorter in patients who received primed BM versus a matched historical control group who received steady-state BM, whereas the incidence of acute and chronic GvHD was similar in both groups.
Ji et al. 37 published a study of 50 patients with CML, who were allocated to receive HLA-matched related marrow transplantation with and without G-CSF donor priming in prospective randomized study. Thirty-two patients (study group) received the marrow graft primed with G-CSF at 3-4 μg/kg/day for 7 days before collection and 18 patients (control group) received the marrow graft without G-CSF-priming. There was a faster engraftment in both neutrophil and platelet in the study group, which was statistically significant. The incidence of grade II-IV acute GvHD was surprisingly low in the study group (6.3%) in comparison with the control group (27%; P = 0.032).
Ostronoff et al. 38 reported a single-center study from Brazil, of 38 allogeneic transplants using G-BM from related donors. Donors received 5 μg/kg/day for 5 days before BM collection. The incidence of acute and chronic GvHD was lower than that observed in the historical BM and PBSC transplantation control groups, although they received only three versus the usual four doses of methotrexate.
Three studies, which compared G-CSF-mobilized PBSC and G-BM from related donors have been reported (Table 3) .
Serody et al. 21 reported on two sequential non-randomized analyses of 20 patients who received G-CSF-mobilized PBSCs versus 26 patients who received G-BM. All donors received 10 μg/kg G-CSF for 4 days. The median time to neutrophil recovery was similar in both groups and there was non-statistically significant trend to faster platelet recovery in the PBSC group. The incidence of grade II-IV acute GvHD at day 90 post transplantation in the cohort that received PBSC (60%) was higher compared with marrow (27%; P = 0.07). At 1 year post transplantation, however, there was a significant increase in the incidence of chronic GvHD in PBSC patients 68% compared with BM patients 37% (P = 0.049).
Elfenbein et al. 39 reported that G-CSF-primed HLA-identical related-donor marrow stem cells engrafted in 11 patients as rapidly as G-CSF-mobilized PBSC in 18 patients who received either graft source after donor treatment with 3 days of G-CSF at 10 μg/kg/day.
Morton et al. 22 published a trial of 57 consecutive patients randomized to G-BM-(28 patients) and G-CSF-mobilized PBSCs (29 patients). Donors received G-CSF (10 mg/kg/day) for 5 days. Median time to neutrophil recovery was 16 days (range 12-23) using G-BM compared with 14 days (range 10-23) for G-PBSC recipients (P o 0.1), whereas median to platelet recovery was 14 days (range 9-22) after G-BM and 12 days (range 8-25) after G-PBSC transplantation (Po 0.1). The incidence of grade III-IV acute GvHD (steroid dependent or refractory) was 47% and 18% in the G-PBSC and the G-BM group, respectively (P = 0.09).
In summary, it appears from the available evidence that G-BM results in faster neutrophil and platelet engraftment when compared with unstimulated BM. It appears similar to G-CSFmobilized PBSC in the rate of neutrophil engraftment and perhaps slightly slower in the rate of platelet engraftment. More significantly G-BM seems to result in less acute and chronic GvHD when compared with G-CSF-mobilized PBSC, but is not different from unstimulated BM. Thus, this graft source may offer the speed of PBSC engraftment with the reduced GvHD.
The reason for less chronic GvHD in G-BM may be related to lower T-cell responsiveness and easier polarization of T cells from Th1 to Th2 in G-BM and also to significantly lower numbers of pDC associated with lower expression of adhesion receptors. 40 Recently, a phase III randomized multicenter trial of matched sibling G-CSF-primed PB versus G-BM was completed by the Canadian Bone Marrow Transplant Group. 41 Between 2007 and 2012, 230 donor-recipients pairs aged 16-65 years received myeloablative conditioning (Bu/Cy and Cy/TBI) with a combination of cyclosporine and methotrexate as GvHD prophylaxis. The majority of patients of this study had AML (49%), ALL (26%), myelodysplastic syndromes/myeloproliferative disorders (14%) and CML (6%), and remaining patients had lymphoproliferative 
Less aGvHD III-IV in G-BM arm
Abbreviations: CI = confidence interval; G-BM = G-CSF-primed bone marrow; LFS = leukemia-free survival; NA = not applicable; OS = overall survival; Plt = platelet; TNC = total nucleated count; TRM = transplantationrelated mortality.
a Significant values.
G-BM as source of stem cells U Deotare et al disorders (5%). The median volume of BM collected was 1127 ml and 94% of the donors underwent only one PBSC collection. The median nucleated cell per kg dose and CD34+ cell dose were higher in the G-PB arm as compared with the G-BM arm (7.6 vs 6 × 10 8 total nucleated count/kg (P o 0.0001) and 5.5 vs 3.2 × 10 6 CD34 cells/kg (P o0.0001), respectively). The neutrophil engraftment was 17 versus 20 days and platelet engraftment was 18 versus 21 days in favor of G-PB arm. With the median follow-up of 3 years, the overall survival (OS) in G-PB arm was 56.8% versus 60.4% in G-BM arm, which was not statistically significant (P = 0.89). The cumulative incidence of extensive chronic GvHD was 63 in G-PB arm and 59 in G-BM arm. The relapse or progression rates and mortality were similar in both the arms. The authors concluded that the neutrophil and platelet recovery was faster in G-PB arm with non-significant trends to less grades 3-4 acute GvHD (G-BM = 3.8%, G-PB = 9.9%, P = 0.09) and less chronic GvHD in G-BM arm (G-BM = 68.4%, G-PB = 80.9%, P = 0.03). 41 
EFFECT OF USE OF FILGRASTIM POST TRANSPLANTATION
Earlier G-CSF was used to hasten engraftment in the posttransplantation course in the allogenic stem cell transplant setting. In an European Bone Marrow Transplant Group study, the effect of the use of G-CSF given after allogenic stem cell transplantation was studied. 42 Among the BMT and PBSC patients, 501 and 175, respectively, were treated with G-CSF during the first 14 days after the transplantation. In the BMT patients, acute GvHD grades II-IV was 50% in the G-CSF group versus 39% in the controls (RR: 1.33; P = 0.007, in the multivariate analysis). The incidence of chronic GvHD was also increased (RR: 1.29; P = 0.03). G-CSF was associated with an increase in transplantation-related mortality (RR: 1.73; P = 0.00016) and had no effect on relapse but reduced survival (RR: 0.59; P = 0.0001) and leukemia-free survival rates (RR: 0.64; P = 0.0003). No such effects of G-CSF were seen in patients receiving PBSC. However, in a Center for International Blood and Marrow Transplant Research study 43 of 1435 recipients with BM as the source and 609 with PBSC grafts, in HLA-identical sibling donors and 675 recipients of matched unrelated donor BM grafts, G-CSF shortened the post-transplantation neutropenic period, but did not affect days 30 and 100 treatment-related mortality. Probabilities of acute and chronic GvHD, leukemia-free survival and OS were similar whether or not G-CSF was given. They concluded that there was no long-term benefit or disadvantage of giving G-CSF after transplantation to promote hematopoietic recovery. In a mouse model, stimulation of host DCs by G-CSF subsequently unleashed a cascade of events characterized by donor natural killer T-cell activation, IFN-γ secretion and CD40-dependent amplification of donor cytotoxic T-lymphocyte function during the effector phase of GvHD. Crucially, the detrimental effects of G-CSF were only present when it was administered after TBI conditioning and at a time when residual host APCs were still present, perhaps explaining the conflicting above clinical studies. 44 
DONOR SAFETY
The collection of hematopoietic progenitor cells from the marrow or PB of normal donors is generally a safe procedure, although both immediate and late complications have been described.
The process of BM donation involves general or spinal anesthesia followed by repeated placement of large bore needles into the posterior iliac crests. [45] [46] [47] Full recovery after donation occurs in 63% of donors within 2 weeks, 24% between 2 and 4 weeks, whereas 13% of donors take more than a month. Complications include mechanical injury, those related to anemia and the need for red cell transfusion, tracheal intubationrelated complications, local infection and anesthetic-related complications.
Complications of PBSC donation include the short-term toxicities associated with either G-CSF administration (local reactions, pain and flu-like symptoms), those associated with placement of a central venous catheter when peripheral access is inadequate (infection, bleeding and pneumothorax) and difficulties with leukopheresis (bleeding secondary to anticoagulation and hypocalcemia). Symptoms generally resolve a few days after G-CSF is stopped or if calcium is given with the apheresis.
There is a concern of increasing the risk of development of hematological malignancies or an increase in vascular and autoimmune disease with the administration of G-CSF to normal donors. 48 Anecdotal reports have been published describing the development of leukemia after G-CSF-primed PBSC donation. [49] [50] However, three small studies of normal adult PBSC donors did not show clinically significant changes in white cell numbers and no donor leukemia was noted. [51] [52] [53] In a recent analysis, 203 healthy volunteer donors were followed up actively for 5 years after G-CSF-mobilized PBSCs were collected. 54 At the first follow-up of 4 weeks, all clinical and laboratory parameters had normalized to premobilization work-up levels. There were no cases of leukemia detected in the observation time of 500 donor years. 54 With G-BM donation, the donor is obviously exposed to both the BM collection risk and those risks related to G-CSF administration. As several studies had addressed the safety of BM donation and G-CSF use with uncertain, rare, serious, longterm side effects, a longer follow-up is required. [55] [56] [57] [58] QUALITY OF LIFE ISSUES A prospective longitudinal investigation was carried out to describe and compare the donation-related HRQoL (quality of life) experiences of 332 BM and PBSC donors. 59 Donors were interviewed before donation, 48 h after donation, weekly until fully recovered and at 6 and 12 months after donation. Before donation, BM donors had lower confusion, fewer concerns and were more prepared for donation. Shortly after donation, BM donors reported more physical side effects. BM donors also reported more donation-related impact on their social activities. Abbreviation: BM = bone marrow.
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However, BM donors reported somewhat better psychological status and were more likely to indicate that the donation made their lives more meaningful. There were virtually no longer-term differences in the experiences of the two donor groups, including no recovery time difference beginning 3 weeks after donation. Although BM donors may experience the process as more physically stressful and more psychologically beneficial in the short term, the longer-term HRQoL consequences of BM and PBSC donors are similar. 59 Another study included 275 PBSC and 37 BM consecutive donors who completed the SF-36 questionnaire predonation and 4 weeks, and 3 months post donation. 60 Predonation HRQoL markers were the strongest predictors of time to recovery. Poorer predonation physical health was associated with longer recovery (P = 0.017) and certain side effects in PBSC donors. Poorer predonation mental health was associated with longer recovery in BM donors (P = 0.03) and pain after PBSC donation (P = 0.003). Physical HRQoL scores declined significantly from predonation to 4 weeks postdonation. This was shown both for PBSC and BM donors (P o 0.001 and P = 0.009, respectively), but the decline was much greater for BM donors. There was a return to predonation HRQoL values 3 months after donation in both groups, with values well above the mean of the general population (Po 0.001).
RESURGENCE OF G-BM USAGE IN HAPLOIDENTICAL TRANSPLANT SETTINGS
The use of G-CSF stimulated BM as the source of stem cells have resurfaced recently in the haploidentical transplant settings. Wang et al. 61 reported the use of haploidentical transplants in 756 patients and reported their 9 years follow-up. The source of stem cells was a combination of G-BM and PBSC without in vitro T-cell depletion. The incidence of grades II-IV acute GvHD was 43% and the 2-year cumulative incidence of total chronic GvHD was 53%. The 3-year cumulative incidence of non-relapse mortality was 18%. The 2-year cumulative incidences of relapse were 15% and 26% in the standard-risk and high-risk groups, respectively. The authors concluded that G-BM combined with PBSC from haploidentical donors, without in vitro T-cell depletion, is a reliable source of stem cells for transplantation. 61 In another multi-center study by Di Bartolomeo et al., 62 80 patients with high-risk hematologic malignancies underwent unmanipulated, G-BM transplantation from a haploidentical family donor. The 100-day incidence for II-IV and III-IV grade of acute GvHD were 24% and 5%, respectively, and 2-year incidence of extensive chronic GvHD was only 6%. The 3-year probability of overall and disease-free survival for standard-risk and high-risk patients were 54% and 33%, and 44% and 30%, respectively. The conclusion from this study was that unmanipulated, G-BM transplantation from haploidentical family donor provides very encouraging results in terms of engraftment rate, incidence of GvHD and survival, and represents a feasible, valid alternative for patients with high-risk malignant hematologic diseases. 62 The use of post-transplant cyclophosphamide as means of in vivo T-cell depletion in haploidentical transplants, especially from John Hopkins Hospital, has added a fresh breath to the use of BM as the source of stem cells. Post-transplant cyclophosphamide facilitates partially HLA-mismatched HSC transplantation without severe GvHD and can mitigate if not completely nullify the negative impact of HLA-disparity on transplantation outcomes. However, G-BM use has not been studied in combination with posttransplant cyclophosphamide in this group of patients and is a potential for future research.
CONCLUSIONS
The source of stem cells, G-CSF-mobilized PBSC, G-BM, or steadystate BM, has an important role in predicting the outcome of allogeneic HSC transplantation in terms of engraftment, survival and the incidence of GvHD. A meta-analysis of studies comparing G-CSF-stimulated BM with PBSC found similar rates of engraftment, acute GvHD, relapse and OS but greater risk of chronic GvHD with PBSC [63] [64] (Table 4) . Two main factors need to be considered, First, the dose of CD34+ cells has an important role, as there is a dose-response relationship of CD34+ cells in related and unrelated donor BM or G-PBSC and clinical outcomes such as engraftment, chronic GvHD and OS. Higher CD34+ cell doses lead to better recovery of neutrophils and platelets, although the clinical significance of that improved recovery is debatable. With related BM transplant, there is no apparent association of CD34+ cell dose with chronic GvHD or OS, but with unrelated BM, higher CD34+ cell dose does seem to result in improved survival. In the related G-PBSC setting, higher CD34+ cell dose (410 × 10 6 /kg) is associated with more chronic GvHD. [65] [66] [67] Second, functional damage to the host marrow microenvironment through prior therapy and the malignant disease itself cannot be overcome by either increasing stem cell dose or using a graft with different stem cell composition. 68 It is quite clear from the previous studies that G-BM contains more CD34+ cells when compared with steady-state BM, and that is reflected in faster neutrophil and platelet engraftment and almost identical to G-CSF-mobilized PBSC in at least neutrophil engraftment and to a lesser extent platelet engraftment. G-BM appears to be associated with less GvHD when compared with G-CSF-mobilized PBSC (Table 5) . Although G-CSF-mobilized PBSC is associated with increased risk of chronic GvHD as demonstrated by the meta-analysis of nine randomized trials, but effect on OS is not statistically significant, However, PBSCT is associated with an increase in both survival and disease-free survival in advancedstage disease. 69 In a recent Center for International Blood and Marrow Transplant Research study, 70 severe aplastic anemia patients who received allografts between 1997 and 2003, received either G-BM (78 patients), BM (547 patients) or PBSC (134 patients) from HLA-matched sibling donors. They concluded that grade II-IV acute GvHD and chronic GvHD were higher after PBSC as compared with G-BM and BM. This study warranted cautious use of PBSC as graft source for severe aplastic anemia.
In summary, G-BM in a few controlled indications may provide similar rates of engraftment to PBSC but possibly with a lower risk of chronic GvHD.
RECOMMENDATIONS
We finally propose the use of G-BM as the source of stem cells in the following two scenarios. First, in the case of severe aplastic anemia and other benign hematopoietic disorders, when we need faster engraftment with reduced GvHD. Second, G-BM may be used in related donors who are children, where the risks and logistic considerations of putting patients on cell separators outweighs the benefits of such a procedure. The convenience of subjecting these children to BM collection might be better as compared with cell separators. Although G-CSF-mobilized PBSC can be used in other remaining conditions when the risk of GvHD is low or with more advanced malignant diseases where graft versus leukemia effect is essential. However, in all these indications, the convenience, utilization of additional resources with financial and logistic implications, cost involved and experience of the transplant centre need to be taken into account.
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